{"abstract": "Crucell, the Dutch biotechnology firm, said Monday that Johnson & Johnson had bought 14.6 million new Crucell shares for $443.5 million as part of a flu vaccine development deal.", "web_url": "https://dealbook.nytimes.com/2009/09/28/johnson-johnson-invests-444-million-in-crucell/", "snippet": "Crucell, the Dutch biotechnology firm, said Monday that Johnson & Johnson had bought 14.6 million new Crucell shares for $443.5 million as part of a flu vaccine development deal.", "lead_paragraph": "Dutch biotechnology firm Crucell said on Monday Johnson & Johnson had bought 14.6 million new Crucell shares for 302 million euros ($443.5 million) as part of a flu vaccine development deal.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Johnson & Johnson Invests $444 Million in Crucell", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-09-28T09:54:49+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/da5dc1b3-fa1c-581b-a9d3-e0db1c1594ec", "word_count": 237, "uri": "nyt://article/da5dc1b3-fa1c-581b-a9d3-e0db1c1594ec"}